115,825 Shares in AbbVie Inc. $ABBV Acquired by Cornerstone Advisors LLC

Cornerstone Advisors LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 115,825 shares of the company's stock, valued at approximately $29,146,000. AbbVie accounts for approximately 1.0% of Cornerstone Advisors LLC's portfolio, making the stock its 23rd largest holding.

Several other large investors have also recently bought and sold shares of ABBV. Tortoise Investment Management LLC lifted its stake in shares of AbbVie by 7.6% in the second quarter. Tortoise Investment Management LLC now owns 1,128 shares of the company's stock valued at $284,000 after buying an additional 80 shares during the period. Auxano Advisors LLC boosted its stake in shares of AbbVie by 3.2% in the 2nd quarter. Auxano Advisors LLC now owns 4,344 shares of the company's stock valued at $1,093,000 after purchasing an additional 134 shares in the last quarter. Argyle Capital Partners LLC boosted its position in AbbVie by 4.6% in the second quarter. Argyle Capital Partners LLC now owns 9,306 shares of the company's stock valued at $2,342,000 after buying an additional 413 shares in the last quarter. Quent Capital LLC increased its holdings in AbbVie by 6.3% during the 2nd quarter. Quent Capital LLC now owns 9,570 shares of the company's stock valued at $2,408,000 after purchasing an additional 565 shares in the last quarter. Finally, IMG Wealth Management Inc. raised its holdings in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock valued at $40,000 after buying an additional 153 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi regulatory expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of Skyrizi in adults with moderately to severely active Crohn’s disease. If approved, the less invasive option could improve patient convenience, strengthen Skyrizi’s European franchise and support longer-term immunology revenue. The filing is backed by positive Phase 3 AFFIRM data. AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
• Positive Sentiment: Additional IBD pipeline investment: AbbVie is conducting a Phase 2 platform basket trial evaluating potential treatments across Crohn’s disease and ulcerative colitis. The study adds longer-term pipeline optionality and may help diversify growth beyond existing immunology products, although it remains an early-stage catalyst. AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial
• Neutral Sentiment: Income-oriented appeal: Recent market commentary highlights AbbVie among established dividend stocks, reinforcing its defensive profile and appeal to income investors. This is supportive of sentiment but does not represent a new company-specific announcement. 3 Dividend Stocks, 12 Paychecks a Year
• Negative Sentiment: Valuation risk: With ABBV trading at a high earnings multiple and close to its 52-week peak, investors may be concerned that substantial future growth is already reflected in the share price. Any regulatory delay or disappointing pipeline data could therefore produce an outsized reaction. Has AbbVie Stock Become Too Expensive to Buy?

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.06% of the stock is owned by company insiders.

AbbVie Stock Performance

ABBV stock opened at $256.08 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47. The company's 50-day simple moving average is $252.66 and its 200 day simple moving average is $228.87. The company has a market capitalization of $452.44 billion, a PE ratio of 72.34, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the previous year, the company posted $2.97 earnings per share. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's dividend payout ratio is presently 195.48%.

Analyst Ratings Changes

A number of research analysts have commented on ABBV shares. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. HSBC reaffirmed a "buy" rating and set a $300.00 price target on shares of AbbVie in a research report on Monday, July 6th. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th. Finally, Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the company an "overweight" rating in a research note on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $275.95.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source